Rapamycin, sirolimus ( DrugBank: Sirolimus, Rapamycin )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
89	Lymphangioleiomyomatosis	1
158	Tuberous sclerosis	1

89. Lymphangioleiomyomatosis

---

Clinical trials : 39 /  Drugs : 46 - (DrugBank : 20) / Drug target genes : 27 - Drug target pathways : 137

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00457808 (ClinicalTrials.gov)	December 2002	6/4/2007	Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM	Rapamycin Therapy of Angiomyolipomas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis	Tuberous Sclerosis;Lymphangioleiomyomatosis	Drug: Rapamycin, sirolimus	Children's Hospital Medical Center, Cincinnati	The LAM Foundation;Tuberous Sclerosis Alliance	Completed	18 Years	65 Years	Both	25	Phase 2	United States

158. Tuberous sclerosis

---

Clinical trials : 108 /  Drugs : 67 - (DrugBank : 17) / Drug target genes : 35 - Drug target pathways : 118

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00457808 (ClinicalTrials.gov)	December 2002	6/4/2007	Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM	Rapamycin Therapy of Angiomyolipomas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis	Tuberous Sclerosis;Lymphangioleiomyomatosis	Drug: Rapamycin, sirolimus	Children's Hospital Medical Center, Cincinnati	The LAM Foundation;Tuberous Sclerosis Alliance	Completed	18 Years	65 Years	Both	25	Phase 2	United States